Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWP14012 + meloxicam
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**DWP14012 + meloxicam** is an investigational combination therapy consisting of DWP14012 (also known as Abeprazan), a small molecule potassium-competitive acid blocker (P-CAB), and meloxicam, a nonsteroidal anti-inflammatory drug (NSAID)[2][4][7]. DWP14012 is being developed as an alternative to proton pump inhibitors for the treatment of acid-related disorders, showing rapid and sustained gastric acid suppression[2][4]. Meloxicam is a preferential COX-2 inhibitor NSAID used for pain and inflammation associated with osteoarthritis and rheumatoid arthritis[1][7]. The combination is being studied to evaluate interactions and safety when DWP14012 is given with NSAIDs like meloxicam, mainly in the context of gastrointestinal safety and potential clinical utility for patients requiring both acid suppression and anti-inflammatory therapy[5].
- Other names
- Abeprazan + meloxicam
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on DWP14012 + meloxicam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWP14012 + meloxicam.